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ABSTRACT  
BACKGROUND: Pseudohypoparathyroidism type Ib (PHP-Ib) is due to epigenetic changes at the 
imprinted GNAS locus including loss of methylation at the A/B differentially methylated region 
(DMR) and sometimes at the XL and AS DMRs and gain of methylation at the NESP DMR.   
Objective: To investigate if quantitative measurement of the methylation at the GNAS DMRs 
identifies subtypes of PHP-Ib.  
DESIGN AND METHODS: In 19 patients with PHP-Ib and 7 controls, methylation was 
characterized at the four GNAS DMRs through combined bisulfite restriction analysis and quantified 
through cytosine-specific real-time PCR in blood lymphocyte DNA.   
Results: A principal component analysis using the percent of methylation at 7 cytosines of the GNAS 
locus provided three clusters of subjects (controls n=7, autosomal dominant PHP-Ib with loss of 
methylation restricted to the A/B DMR n=3 and sporadic PHP-Ib with broad GNAS methylation 
changes n=16) that matched perfectly the combined bisulfite restriction analysis classification. 
Furthermore, we identified three sub-clusters of patients with sporadic PHP-Ib that displayed different 
patterns of methylation:  incomplete changes at all DMRs compatible with somatic mosaicism (n=5), 
profound epigenetic changes at all DMRs (n=8), and unmodified methylation at XL in contrast with 
the other DMRs (n=3).  Interestingly, PTH level at the time of diagnosis correlated with the percent of 
methylation at the A/B DMR. 
Conclusion: Quantitative assessment of the methylation in blood lymphocyte DNA is of clinical 
relevance, allows the diagnosis of PHP-Ib, and identifies subtypes of PHP-Ib. Our epigenetic findings 
suggest mosaicism at least in some patients.   
 
KEY TERMS: pseudohypoparathyroidism, quantitative methylation, subtypes, somatic mosaicism 
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INTRODUCTION 
Parental imprinting refers to mechanisms that lead to the repression of gene expression from one 
parental allele. Genes subjected to parental imprinting are usually clustered in regions rich in CpG 
dinucleotides and contain imprinting control elements in differentially methylated regions (DMRs). In 
most loci, the parent-specific expressed transcripts are associated with a pattern of non or low 
methylated DNA, whereas the non expressed transcripts are associated with a pattern of methylated 
DNA (1). 
 
GNAS is an imprinted locus that produces several transcripts comprising Gsα, the alpha stimulatory 
subunit of the G-protein, XL, A/B (also referred as 1A), NESP and the antisense transcript AS. Due to 
differential methylation of their promoters, most transcripts originate from one parental allele only. 
XL, A/B and AS are transcribed from the paternal allele ; NESP is transcribed from the maternal allele 
only (2) (3).  The promoter of Gsα is not differentially methylated and therefore, Gsα expression arises 
from both alleles in most tissues (Figure 1). However, due to a yet incompletely understood 
imprinting mechanism, Gsα is expressed from the maternal allele only in several tissues including the 
renal proximal tubule, the thyroid, the pituitary and the gonads (4) (5) (6).   
 
Pseudohypoparathyroidism type Ib (PHP-Ib) is a rare disease characterized by the development of 
hormonal resistance comprising PTH resistance and mild TSH resistance (7). Affected patients display 
no or mild features of Albright hereditary osteodystrophy (obesity, short stature, ectopic ossifications 
and bone shape abnormalities), i.e. findings that were initially described in pseudohypoparathyroidism 
type Ia (PHP-Ia) (8) (9) (10). In contrast to patients with PHP-Ia who carry heterozygous loss of 
function mutations of the Gsα coding sequence (11) (12), patients with PHP-Ib do not have mutation 
in the coding sequence of Gsα, but present with epigenetic changes at one or several of the promoters 
of the GNAS locus (13). 
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Based on the extent of these epigenetic changes, PHP-Ib has now been divided in different categories.  
In affected patients, the loss of methylation at the maternal A/B DMR of GNAS is associated with 
decreased Gsα expression in imprinted tissues and PTH resistance. In the autosomal dominant form of 
PHP-Ib (AD-PHP-Ib) caused in most patients by a maternally inherited 3-kb deletion within the 
coding sequence of the STX16 gene (14), and in one family by a maternally inherited 4.3-kb 
overlapping the 3-kb deletion by 1.2-kb (15). Affected individuals show a loss of methylation 
restricted to the maternal A/B DMR of GNAS. Both deletions remove an imprinting control element 
(ICE) located ≈220 kb upstream of the exon A/B of GNAS (Figure 1). The paternal transmission of 
those deletions does not affect the methylation of the A/B DMR of GNAS, nor Gsα expression (14) 
(15).  In addition to those deletions within the STX16 gene, two deletions removing an ICE close to the 
AS and NESP DMRs have been described in three families so far (16) (17). In addition to the loss of 
methylation at the A/B DMR, the maternal transmission of these deletions is associated with 
methylation changes at other DMRs of GNAS on the maternal allele, i.e. loss of methylation at XL and 
AS, gain of methylation at NESP. Besides familial PHP-Ib, most patients are the unique affected 
individual of their family and thereafter considered as sporadic (sporPHP-Ib). The patients affected 
with sporPHP-Ib usually show broad methylation changes at their maternal GNAS locus. Although the 
loss of methylation at the A/B DMR of GNAS is constant in affected patients and confirms the 
diagnosis of PHP-Ib, the methylation changes have been described by us and others as uneven at the 
AS, XL and NESP DMRs (13) (18) (19) (9) (20). 
 
We propose that the different epigenetic patterns observed in patients with sporPHP-Ib likely reflect 
different underlying causes of the disease. In order to test our hypothesis, we quantified and compared 
the methylation of cytosines at four DMRs of GNAS in patients affected with AD-PHP-Ib, sporPHP-Ib 
and controls. The epigenetic patterns were then correlated to the clinical and biochemical features of 
the patients. 
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PATIENTS AND METHODS 
Patients 
Seven controls and 19 subjects affected with PHP-Ib were analyzed. Five patients, comprising one 
(PHP1) affected with AD-PHP-Ib and carrying a maternal STX16 deletion, and four affected with 
sporPHP-Ib (PHP4, PHP14, PHP15 and PHP17) have been previously reported in (19) (9).  
When available, age at diagnosis, features of Albright osteodystrophy (height, body mass index, 
ectopic ossification, brachydactyly) and hormonal resistance (calcemia, phosphatemia, serum level of 
PTH, TSH, 25-OH vitamin D) were recorded retrospectively from medical files. Because the diagnosis 
of the disease was made in different hospitals, the laboratory techniques used to measure calcium, 
phosphorus, PTH, TSH and 25-OH vitamin D levels are different.  Except for one patient (PHP1) 
diagnosed more than twenty years ago, all PTH assays were immunometric and measured the intact 
PTH.  Clinical and biochemical characteristics of the patients at diagnosis (before any treatment) are 
provided in Table 1. Magnesium levels were available for 2 patients only, therefore are not provided 
here. All patients gave their informed consent for the genetic and epigenetic studies. For the present 
report, characterization of the methylation through combined bisulfite restriction analysis and 
quantification of the methylation at the four DMRs of GNAS were performed in all patients, including 
those previously reported. 
 
Detection of the STX16 deletion, exclusion of a deletion within NESP and analysis of the 
methylation at the four DMRs of GNAS 
The search for the common 3-kb deletion within STX16 and the determination of the methylation 
pattern of the GNAS locus through digestion of PCR amplified DNA after bisulfite treatment 
(combined bisulfite restriction analysis) were performed as previously described (9) except that A/B 
and AS DMRs were each amplified using a single PCR.  
In order to exclude a monoallelic deletion removing the NESP exon, we amplified one target sequence 
of the NESP exon located in the genomic sequence that is removed by the two deletions described in 
some patients with PHP-Ib (16) through quantitative real-time PCR. We compared the results to that 
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of the amplification of a single-copy gene MYH9. This approach was first validated in controls by 
comparing amplification of two target sequences within the NESP exon and two reference genes 
(MYH9 and RB1) as performed by Soufir and coll. (21). Primers are provided in Supplementary 
Table 1. 
The quantification of the methylation was adapted from Thomassin et al. (22).  Genomic DNA was 
treated with sodium bisulfite in agarose beads (23), amplified by PCR and analyzed by real-time PCR 
using primers specific for differentially methylated cytosines. For each cytosine analyzed, two primer 
sets were designed using the oligo6 software : a non discriminative (ND) primer pair allowing the 
quantification of the sum of methylated and unmethylated DNA and a discriminative (D) primer pair 
allowing the quantification of the methylated PCR products only (Supplementary Figure 1). This D 
primer is designed so that its most 3’ nucleotide is a locked nucleic acid (LNA) and is complementary 
to the cytosine analyzed. The presence of the LNA at the 3’ end of the D primer ensures an efficient 
discrimination between methylated and unmethylated DNA. Real-time amplification was performed 
using 2 µL of PCR product diluted at 1/104 as reported in Supplementary Table 1 using the 
LightCycler® 480 SYBR Green I Master Mix (Roche Applied Bioscience).  For each DMR, 
experiments were performed in duplicates on two different cytosines except for NESP (only one 
cytosine due to the impossibility to identify accurate primers for an additional cytosine). Three DNAs 
were included in each experiment and served as internal controls to ensure repeatability.  When 
measured onto two distinct bisulfite conversions of controls DNA, the quantification of the 
methylation provided similar results. For each experiment, linear correlations (r2>0.90 and p<0.05) 
between theoretical and measured percent of methylation were built using mixtures of PCR products 
obtained from amplification of bisulfite treated methylated and unmethylated DMR matrices inserted 
in TOPO-TA cloning plasmids (Invitrogen, Cergy-Pontoise, France). The standard curves were 
constructed using an increment of 5 between 0 and 40% of methylated DNA, and an increment of 10 
between 40 to 100 % of methylated DNA (Supplementary Figure 1, panel b). The slope and y-
intercept of these linear correlations were used to normalize the percent of measured methylation (see 
below). At a given cytosine, the percent of measured methylation was calculated using the following 
equations:  
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Percent of measured methylation = [100 x (1+END)CtND/(1+ED)CtD ] – background, in which  
Background = 100 /(1+E) ΔCt(UnMT-MT) 
where E is efficacy of amplification, Ct is cycle threshold, UnMT and MT are totally unmethylated 
and methylated DNA matrices, respectively.   
The results are presented as percent of methylation normalized using the equation: 
Percent of methylation = slope(linear correlation) x percent of measured methylation + y-intercept(linear 
correlation) 
The percent of methylation measured at two distinct cytosines of each DMR (A/B, XL and AS) were 
highly correlated (Supplementary Figure 2). Therefore values are provided throughout the 
manuscript and figures for one representative cytosine (AB2 for A/B, AS2 for AS, XL1 for XL and 
NE for NESP) except if mentioned otherwise. Except for XL2, the cytosines studied by real-time PCR 
were different from those analyzed by the combined bisulfite restriction analysis (Supplementary 
Figure 1, panel a). 
The quantification of the methylation at the A/B DMR of GNAS was confirmed using pyrosequencing 
(methods in Supplementary data). 
 
Statistical analysis 
Quantitative measures of the patients characteristics (clinical and biochemical) are presented as 
median ± standard error (SE) and quantitative measures of methylation are presented as mean ± SE.  
For the identification of clusters of patients based on quantitative measures of methylation, 
hierarchical classification, allowing a dendrogram representation, was deduced from the percent of 
methylation at the 7 cytosines of the four DMRs using euclidean distance and Ward method.  
Euclidean distances were computed between individuals, then the closest ones were merged into a 
cluster.  Distances between clusters are defined by the Ward formula. Euclidean distance is the square 
root of the sum of squares of differences between each coordinate of two points. For example, if we 
have two points x and y defined by two coordinates (x1,x2) and (y1,y2) respectively, the Euclidean 
distance between them is sqrt((x1-y1)^2+(x2-y2)^2). Ward distance is exactly the same but it is based 
on the coordinates of the cluster centroids and is weighted by the cluster sizes. Merging was 
 9
performed until all data were clustered in a single group. The findings were confirmed by a principal 
component analysis (PCA) (24). PCA is a statistical method that reduces the complexity of the 
interrelationships among a large number of variables (7 cytosines of the four DMRs in this report) to a 
small number of linear combinations, referred to as principal components. The first principal 
component is the linear combination of original variables which spreads the data as much as possible. 
Then, the following components are built so that they also maximize the variance of data while 
bringing new information with regards to the previous components (orthogonality between successive 
components). Hence, successive component accounts for decreasing and additive parts of the total 
variability of data. In our study, the first three components accounted for 93% of the variability 
(component 1: 72%, component 2: 13% and component 3: 8%), which renders the study of these three 
principal components highly sufficient. Because the sample sizes are small, the non-parametric 
Kruskal Wallis test was used to compare percent of methylation and clinical characteristics between 
clusters and sub-clusters. The non-parametric multiple comparison test was used to further study the 
differences between pairs of clusters (25). The Wilcoxon Signed Rank Test was used to compare 
height and BMI values to the general population reference (hypothetical value=0). For the correlation 
between variables, degree of significance and confidence interval are provided. Statistical analyses 
have been performed using R and Prism softwares (26).  
 10
 
RESULTS 
Diagnosis of PHP-Ib (Figure 2)  
Three subjects (PHP1, 2, 3) carry the 3-kb STX16 deletion (data not shown) and loss of methylation at 
the A/B DMR of GNAS without additional epigenetic change. The 3-kb STX16 deletion was also 
found in their mothers. The 3-kb STX16 deletion was not found in the 16 remaining patients. As 
expected, these patients displayed loss of methylation at the A/B DMR of GNAS and methylation 
change(s) affecting at least one additional DMR. The quantitative real-time amplification of a target 
sequence within the NESP exon was similar in the 16 patients affected with spor-PHPIb and in 3 
controls than that of one single-copy gene and thus renders unlikely a deletion removing one allele 
(data not shown). DNAs of the two parents of patients PHP4, 12, 13, 14, 16 and 17, of the mother of 
patients PHP9 and 19 and of the siblings of patients PHP16 and 17 were available. None of the parents 
or siblings had methylation abnormalities at the GNAS locus (combined bisulfite restriction analysis). 
Altogether, our cohort of PHP-Ib comprises 3 patients affected with AD-PHP-Ib (PHP1-3) and 16 
patients affected with sporPHP-Ib (PHP4-17). Results for combined bisulfite restriction analysis from 
2 controls, 2 patients affected with AD-PHP-Ib and 4 patients affected with sporPHP-Ib are shown on 
Figure 2, panels a-d.  
 
Identical diagnosis of AD- and sporPHP-Ib patients comparing quantification of methylation 
and combined bisulfite restriction analysis (Figure 2 and 3) 
In all patients affected with PHP-Ib, percent of methylation at the A/B DMR ranged from 1.4 to 
14.9%, a range that was significantly lower than that observed in controls (42.4 to 67.4%) (p=1.21e-
04). No overlap between values measured in PHP-Ib patients and controls was observed. These results 
indicate that the quantification of methylation at the A/B DMR cytosines provides a valid and specific 
diagnosis for PHP-Ib (Figures 2 e and 3 b). 
We confirmed the accuracy of the quantification by measuring the methylation at the A/B DMR 
through pyrosequencing (Supplementary data). 
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Furthermore, as expected, in patients with AD-PHP-Ib, percent of methylation at the AS, XL and 
NESP DMRs (AS: 48.5±9.0%; XL: 46.9±13.3%; NESP: 43.3±5.8%, respectively) were not 
significantly different from that in controls (AS: 46.1±8.5%, p=0,690; XL: 42.8±4.3%, p=0.930; 
NESP: 43.1±7.4%, p=0.924, respectively) (Figures 2 f-h and 3 b). 
In patients with sporPHP-Ib, percent of methylation were significantly lower at the AS and XL DMRs 
(AS: 2.3±6.6%, p=1.15e-06; XL: 18.3±10.9%, p=4.37e-06) and significantly higher at the NESP DMR 
(79.8±17.7%, p=1.90e-05) than those of controls (Figure 2 f-h). 
These results indicate that the quantification of methylation at the AS, XL and NESP DMR cytosines 
provides a reliable diagnosis tool to discriminate between AD-PHPIb with loss of methylation 
restricted to the DMR A/B and sporPHP-Ib with broad methylation changes. 
 
Classification of patients through the quantification of methylation at the four DMRs of GNAS 
(Figure 3 and Supplementary Figure 3). 
Hierarchical classification and PCA using the percent of methylation at the studied cytosines (n=7), 
first performed comparing controls and PHP-Ib patients, provided three clusters (cluster 1, 2 and 3) 
that matched the classification in control, AD-PHP-Ib and sporPHP-Ib groups, respectively, 
established on the basis of the combined bisulfite restriction analysis (Figure 3 and Supplementary 
Figure 3). 
Further analysis of cluster 3 identified three different sub-clusters (designated here as sub-clusters 3.1, 
3.2 and 3.3) reflecting three different patterns of methylation and likely, three different types of 
sporPHP-Ib. For each sub-cluster obtained through PCA, individual percent of methylation at each 
DMR are shown on Figure 3 b. Sub-cluster 3.1 is characterized by incomplete methylation changes at 
AS, XL and NESP DMRs, sub-cluster 3.2 by a methylation at the XL DMR similar to that in controls, 
whereas patients in sub-cluster 3.3 showed profound epigenetic defects at all DMRs investigated.   
 
Correlation epigenotype-phenotype 
Similar to what we and others have previously reported (8) (9), some patients with sporPHP-Ib display 
features of Albright osteodystrophy initially described in patients affected with PHP-Ia (Table 1). 
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PHP9 presented with infracentrimetric subcutaneous ossification and PHP4, PHP17 and PHP12 with 
short metacarpals. The distribution of these patients was equal in the 3.1, 3.2 and 3.3 sub-clusters.  In 
patients with sporPHP-Ib, we also observed a distribution of body mass indexes (BMI) towards 
obesity (mean BMI 1.0 ± 0.4 SD, p=1.9e-02). The females showed a significantly higher BMI than the 
males (2.0 ± 1.0 SD and 0.1 ± 0.9 SD, p=3.5e-03 respectively). However, the mean height for these 
patients (0.6 ± 0.5 SD) does not differ from that of the French reference population (p=0.268) (27). 
One patient with AD-PHP-Ib (PHP1) also presented with an increased BMI (Table 1).   
Interestingly, we found a significant positive correlation between the percent of methylation at the A/B 
DMR and the PTH level at the time of diagnosis (PTH and cytosine AB1: p=5.8e-03, CI 0.20-0.84 ; 
PTH and cytosine AB2: p=4.0e-04, CI 0.38-0.89) (Figure 4 b) and a negative correlation between 
PTH and 25 OH vitamin D levels (p=1.2e-03, CI -0.87-0.11). PTH levels were not influenced by 
gender or the age at diagnosis. 
Serum calcium, phosphate and PTH levels were similar in the 3.1, 3.2 and 3.3 sub-clusters Figure 4 a.  
TSH levels were significantly higher in sub-cluster 3.2 compared to sub-clusters 3.1 and 3.3 (p<0.05 
for both comparisons). TSH levels did not correlate with the percent of methylation at the A/B nor the 
XL DMR. 
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DISCUSSION 
We show here, in a series of 19 patients affected with PHP-Ib, diverse patterns of methylation at the 
GNAS locus. Those results will help to better understand this rare disease. First, we show that sporadic 
PHP-Ib may have different origins reflected by at least three significantly different patterns of 
epigenetic abnormalities. Second, we show for the first time through a quantitative method that 
epigenetic defects are incomplete in some patients. This has been suggested by Liu et al (18) through 
southern-blotting. This may have important consequences for the diagnosis of the disease and the 
genetic counselling in patients. Third, we show a positive correlation between PTH level, a hallmark 
of Gsα function in the kidney, and quantitative methylation at the A/B DMR measured in blood 
lymphocytes where Gsα is not imprinted.  
Heterogeneity in the methylation abnormalities at the GNAS locus in patients affected with PHP-Ib, 
first reported by Liu et al (13), has been since then confirmed by us and others (18) (19) (9) (20). In an 
effort to better characterize these methylation abnormalities, and because we experienced difficulties 
in interpretating the results of the combined bisulfite restriction analysis in a subset of patients affected 
with PHP-Ib, we adapted a quantitative method developed by Thomassin and colleagues (22) to 
measure the methylation at the four DMRs of GNAS locus. Compared to the southern blot which is 
considered as the gold-standard quantitative method, the quantification of methylation through real-
time PCR i) requires ≈20 times less DNA, ii) can be completed within 4 hours after bisulfite 
conversion, iii) allows the analysis of twenty samples in one run.  However, similarly to methods 
relying on enzymatic digestion such as southern-blot or methyl-sensitive assays, or on allele-specific 
hybridization, this method does not allow the analysis of a stretch of cytosines. The latter can be 
performed through pyrosequencing, sequencing of subcloned PCR products or base-specific cleavage 
followed by mass spectrometry after amplification from bisulfite treated DNA (28) (9) (29).   
 
Our results show that the quantification of the methylation at the DMRs of GNAS provides a reliable 
diagnosis of PHP-Ib -i.e. detects loss of methylation at the A/B DMR- and accurately discriminates 
AD-PHP-Ib from sporPHP-Ib (grouped in clusters 2 and 3, respectively in this report). 
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In addition, the quantitative measure of the methylation allowed the identification of three sub-groups 
of sporPHP-Ib (sub-clusters 3.1, 3.2 and 3.3) based on their pattern of methylation at the four DMRs 
of GNAS. Our observations raise several hypotheses as regard to the mechanisms involved in these 
methylation patterns. First, these different patterns may correspond to different causes of methylation 
defects. So far, all elucidated epigenetic changes at the GNAS locus have been linked to the deletion of 
an ICE close to or within GNAS (STX16 and NESP-AS, respectively) in AD-PHP-Ib (14) (16) (15) 
(17). The variable patterns of methylation defects in the GNAS locus that we identified in sporPHP-Ib 
could be due either to a deletion of different (yet-unknown) GNAS ICEs or to partial deletions of a 
single ICE. In agreement with such a possibility, in the 15q11-q13 imprinted locus, numerous 
imprinting center deletions have been identified in patients or generated in mice. Both the phenotype 
of the patients (and mice) and the methylation pattern of the surrounding region depend on the size of 
the deletion (30) (31).  
Alternatively, besides patients with profound epigenetic changes at the GNAS locus, we identified one 
group of patients (sub-cluster 3.1) with moderate methylation changes at all DMRs investigated. This 
pattern would be expected in the presence of somatic mosaicism i.e. the contribution of normal cells 
and cells with an imprinting defect to the embryo. If an epimutation occurs in the gametes, all cells 
should be modified leading to drastic changes in the percent of methylation measured by a quantitative 
method. A range of methylation from 24 to 68 % has been found at the NESP DMR in healthy 
individuals and attributed to epigenetic mosaicism (32). We observe in patients of sub-clusters 3.1 and 
3.2 that the percent of methylation at each analyzed DMR differs within the same patients. In 
particular, the methylation at the XL DMR appeared less affected compared to the A/B, AS and NESP 
DMRs. This may suggest that XL is a secondary DMR in which the parental imprint is inconsistently 
modified whatever the mechanism leading to the observed pattern of methylation, somatic mosaicism 
(sub-cluster 3.1) or another unknown mechanism (sub-cluster 3.2). Such somatic mosaics of 
epigenetic defects have also been proposed in the context of several diseases involving loci submitted 
to parental imprinting. Somatic mosaicism has been found in about one third of the Angelman 
syndrome with imprinting defects at the SNURF-SNRPN gene  and correlated with the severity of the 
disease (33). In patients with Beckwith-Wiedemann syndrome, Bliek and al. reported ratios of 
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unmethylated DMRs ranging from 2.5 to 33 % at KvDMR1 and patterns of both partial and complete 
hypomethylation at other imprinted loci including GNAS in the same patients (34). In patients with 
Silver-Russell syndrome, several groups have now reported that the clinical asymmetry is associated 
with variable degrees of hypomethylation at the H19 gene in accordance with a post-zygotic error of 
the imprinting (35) (36). Noteworthy, this mechanism is compatible with the sporadic occurrence of 
PHP-Ib.  Moderate methylation changes could also result from incomplete methylation pattern along 
the maternal GNAS allele in each cell due to stochastic juxtaposition of methylated and unmethylated 
cytosines at each DMR. In a previous report, we have shown in two patients affected with sporPHP-Ib 
(PHP4, sub-cluster 3.1 and PHP17, sub-cluster 3.3) that the methylation of the cytosines is 
homogeneous along alleles at the four GNAS DMRs (9), thereby rending unlikely stochastic 
modifications of the methylation as the cause of the incomplete methylation changes that we 
measured. Demonstration of somatic mosaicism will require clonal analysis of cells derived from 
affected tissues to show the presence of cells with normal methylation patterns and cells with 
abnormal methylation patterns. 
Uniparental disomy (hetero or isodisomy) has been identified as the cause of diseases of parental 
imprinting (for example Prader-Willi syndrome (31) or maternal UPD 14 syndrome (37)) and in one 
patient affected with PHP-Ib (38). Therefore we cannot exclude that, in some patients, PHP-Ib is due 
to uniparental disomy, especially in patients with the profound epigenetic changes (sub-cluster 3.3 in 
this report). 
 
PTH levels in absence of treatment for PTH resistance were positively correlated with the percent of 
methylation at the A/B DMR of GNAS. Although higher PTH levels are intuitively associated with 
more severe PTH resistance, our findings may suggest that the association of hypocalcemia and mildly 
elevated PTH reflects more severe PTH resistance than hypocalcemia and highly elevated PTH levels.  
As if, in the latter case, low expression of Gsα allows the maintenance of the calcium level and PTH 
signalling at the cost of highly elevated PTH concentration (hypocalcemia occurs with lower levels of 
PTH when A/B is completely demethylated and Gsα not expressed). Differently, the percent of 
methylation at A/B –i.e. the degree of Gsα expression- may indirectly control PTH secretion and/or 
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clearance through a feedback loop. This correlation between PTH levels and the methylation at the 
A/B DMR could be influenced by other factors and should be considered carefully. In fact, PTH levels 
are prone to environmentally-mediated fluctuations, and we have confirmed in this cohort that PTH 
levels were influenced by 25 OH vitamin D levels. Noteworthy, this correlation was established with 
data obtained through different techniques. However, we propose that this correlation between PTH 
and the degree of methylation at the A/B DMR confirms the clinical relevance of studying the 
methylation at the GNAS locus in blood lymphocytes where Gsα is not imprinted.  
 
Comparison of the clinical and biochemical characteristics between sub-clusters of patients with 
sporPHP-Ib showed that serum TSH levels were lower in sub-clusters 3.1 and 3.3 compared to sub-
cluster 3.2. Despite the low number of patients in each group, which does not allow to draw definitive 
conclusions, it is interesting that sub-cluster 3.1 and 3.3 are characterized by a more profound loss of 
methylation at the XL DMR compared to that in sub-cluster 3.2. The loss of methylation at the XL 
DMR likely allows the biallelic expression of XLαs (39), a protein that arises from XL, which shares 
with Gsα  the ability to generate intracellular cAMP (40) (41). One can speculate that increase in XLαs 
expression resulting from lower methylation at the XL DMR may compensate for the Gsα deficiency 
in the thyroid and prevent TSH resistance in patients of sub-clusters 3.1 and 3.3. If this hypothesis is 
true, then patients affected with AD-PHP-Ib, who have a monoallelic expression of XL should have 
elevated TSH levels. In the patients reported here, TSH levels were 4.5 (PHP1) and 1.9 mUI/L (PHP2) 
(normal range: 0.5-4.5 mUI/L).  Interestingly, the TSH level in the patient affected with AD-PHP-Ib 
reported by Mantovani et al is 5.4 (42).  Altogether, these results indicate that some phenotypic 
characteristics of patients may depend on the pattern of methylation at the GNAS locus, yet need to be 
confirmed in a larger cohort of patients. 
 
By the precise characterization of the methylation defects at the GNAS locus in a cohort of PHP-Ib 
patients with PHP-Ib, we have identified different subtypes of PHP-Ib compatible with different 
causes of the disease, including somatic mosaicism. 
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LEGENDS  
Figure 1:  Schematic drawing of the GNAS locus and its 5’ boundary including the STX16 gene.  
The GNAS locus is scaled, based on HG18. The position of the 7 cytosines is indicated by the vertical 
lines and the numbers. The four DMRs studied in this report are represented below the genomic line 
by black boxes (+ or methylated) or white boxes (- or unmethylated) on the paternal (Pat) or maternal 
(Mat) allele (2). CpG islands identified by the Genome Browser software are shown on the lower 
horizontal line. Exons are indicated as black rectangles, repeated sequences as stripped triangles, 
STX16 and NESP-AS deletions as brackets, allelic origin of transcription as broken arrows on the 
paternal (Pat) or maternal (Mat) allele.  
 
Figure 2: Methylation analysis at the four DMRs of GNAS. (a.b.c.d): Electrophoresis on an 
agarose gel after combined bisulfite restriction analysis of genomic DNA at the DMRs A/B, AS, XL 
and NESP in 2 control individuals (CTRL1, CTRL2) and 6 patients affected with PHP-Ib.  At the A/B 
DMR: in all PHP-Ib patients the lower (i.e. methylated or CH3) band is completely or nearly 
completely absent indicating a loss of methylation.  At the AS and XL DMRs: in patients PHP17, 
PHP18, PHP7 and PHP4, the lower (i.e. methylated) band is completely or nearly completely absent 
indicating a loss of methylation, whereas it is present in PHP1, PHP2, CTRL1 and CTRL 2, indicating 
an hemi-methylation.  At the NESP DMR: in patients PHP17, PHP18, PHP7 and PHP4, the upper (i.e. 
unmethylated or un-CH3) band is faint indicating a partial gain of methylation, whereas it is similar to 
controls in PHP1 and PHP2, indicating an hemi-methylation.  (e.f.g.h):  In the same individuals, 
percent of methylation (% CH3) measured at one representative cytosine of each DMR (AB2 for A/B, 
AS2 for AS, XL1 for XL and NE for NESP) are represented as bar graphs.   
 
Figure 3: Identification of different subtypes of PHP-Ib. a. Cluster dendrogram obtained after 
quantification of the methylation at 7 cytosines belonging to four DMRs of GNAS.  As exemplified by 
PCA (see methods and Supplementary Figure 3), three main clusters were identified: cluster 1 which 
includes all control individuals, cluster 2 which includes the three AD-PHP-Ib patients, and a larger 
 19
cluster 3 including all patients affected with sporPHP-Ib.  The latter can be further divided in three 
sub-clusters: 3.1, 3.2 and 3.3.  b and c. For each cluster and sub-cluster obtained through PCA, 
individual values for percent of methylation are shown (cytosine AB2 for A/B, AS2 for AS, XL1 for 
XL and NE for NESP).  The mean for each group is indicated by the horizontal line, and significative 
differences between clusters (p value < 0.05) are summarized in the table for each DMR.  
 
Figure 4: Comparison between epigenotypes and phenotypes. a. Box and whisker plots of 
hormonal resistance markers in the patients of sub-clusters 3.1, 3.2 and 3.3.  The shaded area indicates 
the normal range. *: p<0.05 compared to values in sub-clusters 3.1 and 3.3.  b. Significant correlation 
between the percent of methylation at the A/B DMR and PTH levels at the time of diagnosis.  Both 
correlations with cytosines AB1 and AB2 are shown. 
 
Supplementary Figure 1: Quantification of the methylation adapted from Thomassin and 
colleagues (22).  A.  Sequences of the PCR products amplified for the analysis of the A/B, AS, XL 
and NESP DMRs.  Bold and underlined cytosines were studied using the quantitative method, whereas 
bold and italic cytosines were studied using combined bisulfite restriction analysis.  B. Linear 
regression between theoretical and measured methylation at the A/B DMR (Cytosine AB1, r2=0.98, 
p<1.0e-04). C. Schematic drawing of the PCR amplification of a differentially methylated region (the 
unmethylated cytosine on the paternal allele was previously converted by bisulfite treatment in uracile 
then in thymine after the first round of amplification) using non discriminative (black arrows) and 
discriminative (red-lozenge arrow) primers.  The amplification and melting curves after amplification 
of a differentially methylated DNA fragment show the delay in the discriminative (D) compared to the 
non-discriminative amplification (ND).  The melting curves confirm the presence of two different 
PCR products (shown on the right panel) in the same reaction.  
 
Supplementary Figure 2:  Correlations between percent of methylation measured at cytosines AB1 
and AB2, XL1 and XL2, AS1 and AS2.  Degree of significance (p), confidence interval (CI) and r 
squared are provided.   
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Supplementary Figure 3:  Biplots representation of PCA using the quantification of methylation at 
the four DMR of GNAS (seven cytosines).  A biplot is the projection of patients and controls onto two 
distinct principal components.  Variables (quantification of methylation at each cytosine) are shown by 
red arrows; the length of the arrow indicates the weight of each variable ; the opposite direction of the 
NESP cytosine versus the other cytosines illustrates gain versus loss of methylation.  The black 
rectangles delineate clusters and sub-clusters based on the hierarchical classification.  In biplot a 
(component 1 and 2), controls and patients are clearly separated based on quantification of 
methylation at the A/B cytosines.  Within patients, AD-PHP-Ib and sporPHP-Ib are distinguished by 
the methylation at the other DMRs.  In biplot b (component 1 and 3), patients with sporPHP-Ib are 
clearly separated from controls and AD-PHP-Ib.  In this group, three sub-clusters of patients can be 
identified based on the quantification at NESP, XL and AS cytosines. 
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Table 1:  Clinical and biochemical characteristics at diagnosis of the 19 patients affected with PHP-Ib, either AD-PHP-Ib with STX16 deletion and loss of 
methylation restricted to the A/B DMR of GNAS, or sporPHP-Ib with broad GNAS methylation changes.  M: male, F: female; BMI: body mass index; AHO: 
Albright hereditary osteodystrophy; BM: brachydactyly; SCO: subcutaneous ossification; na: not available; no: absence of obvious features of AHO.  Normal 
range for calcemia is 2.25-2.60 mM, phosphatemia: 1-1.8 mM, PTH: 10-60 pg/ml, 25-OH vitamin D (25-OHD): 15-60 ng/ml and TSH: 0.5-4.5 mUI/L.  
Code 
Patient Disease
Gender
(M/F)
Age at 
diagnosis 
(years)
Height  (SD) BMI  (kg/m2) BMI       (SD)
Number of 
family 
members 
studied
Number of 
family 
members 
affected
AHO 
features
Calcemia 
(mM)
Phosphatemia 
(mM) PTH  (pg/ml) TSH (mUI/L)
25-OHD
(ng/mL)
Cluster and 
sub-cluster
PHP1 AD-PHP-Ib M 9.0 -0.4 24.1 0.3 6 2 no 1.7 2.8 na 4.5 12.0 2
PHP2 AD-PHP-Ib F 15.3 na na na na - no 1.4 2.6 890 1.9 6.0 2
PHP3 AD-PHP-Ib M 14.2 na na na 2 0 no 1.3 3.0 197 na 48.0 2
PHP4 SporPHP-Ib F 10.0 0.3 27.5 2.2 2 0 BM 1.4 2.2 169 1.0 21.0 3.1
PHP5 SporPHP-Ib M 14.5 0.7 23.1 1.6 na - no 1.1 2.5 259 5.3 na 3.1
PHP6 SporPHP-Ib M 11.0 5.4 27.7 3.7 na - no 1.7 2.1 551 2.6 25.0 3.1
PHP7 SporPHP-Ib M 7.0 3.4 19.9 2.5 na - no 1.0 3.0 583 2.0 9.0 3.1
PHP8 SporPHP-Ib M 7.0 -0.2 17.8 0.0 na - no 1.8 2.2 386 2.2 na 3.1
PHP9 SporPHP-Ib F 8.0 1.6 23.1 1.4 1 0 SCO 1.2 2.4 572 6.5 9.0 3.2
PHP10 SporPHP-Ib F 26.0 -2.7 26.2 1.2 na - no 1.3 1.9 359 5.5 25.6 3.2
PHP11 SporPHP-Ib F 16.0 0.1 23.0 0.8 na - no 1.7 2.0 195 10.1 32.8 3.2
PHP12 SporPHP-Ib F 26.0 0.1 24.3 0.6 2 0 BM 1.8 1.2 807 2.7 na 3.3
PHP13 SporPHP-Ib M 14.0 0.6 16.8 -1.6 2 0 no 1.2 2.4 603 3.8 na 3.3
PHP14 SporPHP-Ib M 7.0 0.0 24.0 0.4 2 0 no 2.2 2.2 191 3.1 22.0 3.3
PHP15 SporPHP-Ib M 16.0 -1.9 19.4 -0.5 na - no 1.2 2.4 788 3.5 8 3.3
PHP16 SporPHP-Ib F 10.5 3.2 40.9 4.0 4 0 no 1.5 2.2 126 3.6 25.5 3.3
PHP17 SporPHP-Ib M 11.0 -0.3 18.4 -1.1 5 0 BM 1.4 2.2 185 6.6 11.0 3.3
PHP18 SporPHP-Ib M 10.4 -1.6 16.8 0.1 na 0 no 1.3 3.2 410 2.5 9.0 3.3
PHP19 SporPHP-Ib M 13.0 0.7 23.9 1.7 1 0 no 1.3 3.3 232 2.4 na 3.3
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